LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody

Contributed by: Business Wire

Logo

Tags

Research

Venture Capital

Professional Services

Biotechnology

General Health

Pharmaceutical

Health

Science

Oncology

Other Science

LabGenius Therapeutics

More Like This

LabGenius Therapeutics Announces New Collaboration with Sanofi for Multiple AI/ML-driven Antibody Optimisation Programmes

LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 2025

Debiopharm & WhiteLab Genomics Announce a Strategic Partnership to Advance Drug Target and Design in Oncology

Business Wire associated0

Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

PR Newswire associated0

mAIbe and LenioBio announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies